scholarly journals Effects of “Satureja hortensis L.” on Improving Adult Gastroesophageal Reflux Disease: A Double-Blinded, Randomized, Controlled Clinical Trial

2018 ◽  
Vol 20 (2) ◽  
Author(s):  
Amir Hossein Faghihi Kashani ◽  
Ghazaleh Heydarirad ◽  
Seyde Sedighe Yousefi ◽  
Rasool Choopani ◽  
Mohamad Kamalinejad ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Gastroesophageal Reflux Disease ◽  
Gastroesophageal Reflux ◽  
Reflux Disease ◽  
Controlled Clinical Trial ◽  
Randomized Controlled Clinical Trial ◽  
Satureja Hortensis ◽  
Randomized Controlled ◽  
Double Blinded

scholarly journals Efficacy of intravenous infusions of UC-derived MSCs for the treatment of COVID-19: A structured summary of a phase II double blinded, randomized controlled clinical trial

2020 ◽  
Author(s):  
Muhammad Ali ◽  
Azra Mehmood ◽  
Moazzam Nazeer Tarar ◽  
John D Gottsch ◽  
Zafar Nawaz ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Inflammatory Responses ◽  
Standard Of Care ◽  
Convincing Evidence ◽  
Controlled Clinical Trial ◽  
Immune Reactivity ◽  
Randomized Controlled Clinical Trial ◽  
Beneficial Effects ◽  
Randomized Controlled ◽  
Double Blinded

Abstract In this clinical research project, we will conduct a highly rigorous clinical trial where we randomize the patients between umbilical cord (UC)-derived mesenchymal stem cell (MSC) and standard of care (SOC). This study will ask the question whether the allogenic MSCs are effective in reducing death and/or progression of COVID-19 disease when administered to patients with moderate to severe symptoms. MSCs are unique group of cells with minimal immune reactivity and produce multiple beneficial effects, which include reduction of severe inflammatory reaction. There is convincing evidence from human studies that intravenous (IV) delivery of MSCs can directly impact the hyper-inflammatory responses of COVID-19 induced injury of the heart and lungs. Our study will evaluate the safety and efficacy of allogenic UC-derived MSCs administered intravenously to COVID-19 patients with moderate to severe symptom in a randomized, controlled clinical trial. In addition, we will determine whether : (i) UC-derived MSCs are effective in reducing 30-day all-cause mortality (primary endpoint) and (ii) UC-derived MSCs are effective in preventing progression to mechanical ventilation, and/or reducing an inflammatory response, and/or improving overall patient condition (secondary endpoints).

Sign in / Sign up

Export Citation Format

Share Document